Drug Profile
Research programme: infectious disease vaccines - Affinivax
Latest Information Update: 22 Aug 2022
Price :
$50
*
At a glance
- Originator Affinivax
- Class Bacterial vaccines; Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections; Nosocomial infections
Most Recent Events
- 16 Aug 2022 Affinivax has been acquired by GlaxoSmithKline
- 28 Nov 2019 No recent reports of development identified for research development in Nosocomial-infections(Prevention) in USA
- 28 Nov 2018 No recent reports of development identified for preclinical development in Bacterial-infections(Prevention) in USA